当前位置： SCI文献检索 > PHARMACOTHERAPY期刊下所有文献 > Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.

Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.

Abstract：

OBJECTIVES:To examine the knowledge, attitudes, and interest of an inner-city population toward pharmacogenetic testing, with the primary objective of identifying facilitators and barriers toward pharmacogenetic testing; and secondary objectives of determining predictors of patient interest in pharmacogenetic testing and how much patients would pay for the test. METHODS:Patients were recruited from an Antithrombosis Clinic from March to April 2014. A cross-sectional 19-question survey was administered in person to determine patients' knowledge and awareness of pharmacogenetic testing and collect demographic information. After explaining pharmacogenetics, patients ranked their interest toward the test and answered open-ended questions that elicited facilitators and barriers toward pharmacogenetic testing and elucidated how much patients would pay for testing. RESULTS:A total of 120 patients (mean age 55.0 ± 14.0 years, 39.2% male, 69.2% African American) were surveyed. Facilitators included providing further information about pharmacogenetic testing; elaborating on benefits of testing to predict treatment efficacy; patients' trust in their providers to make correct genotype-guided prescribing decisions; and insurance coverage and test affordability. Barriers to testing included concerns about the negative consequences associated with test results; burden of the testing process; perceived lack of utility among elderly and those whose medications were working; privacy issues; and concerns regarding insurance coverage and test affordability. Women had 4.2 times higher adjusted odds of being interested in pharmacogenetic testing. Almost half (44.4%) of the patients with high interest in the test were willing to pay $20 or more, whereas 76.2% of patients with low interest wanted testing at no cost. CONCLUSION:This study identified facilitators, such as providing additional pharmacogenetic test information, and barriers, such as perceived negative impact of the results and test utility, as issues to address when engaging an urban, largely minority population in pharmacogenetic testing. Female sex was a predictor of interest toward pharmacogenetic testing. These facilitators and barriers should be taken into consideration as pharmacogenetic testing gains widespread utility among inner-city populations.

journal_name

Pharmacotherapy

journal_title

Pharmacotherapy

authors

Lee YM,Manzoor BS,Cavallari LH,Nutescu EA

doi

10.1002/phar.2077

subject

Has Abstract

pub_date

2018-02-01 00:00:00

pages

205-216

issue

eissn

0277-0008

issn

1875-9114

journal_volume

pub_type

杂志文章

在线工具

Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.